EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The MSA Atrophy Index ( MSA ‐ AI ): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy

Paula Trujillo iD, Kilian Hett iD, Amy Cooper, Amy E Brown, Jessica Iregui, Manus J Donahue, M Erik Landman, Italo Biaggioni, Margaret Bradbury, Cynthia Wong, David Stamler, Daniel O Claassen iD

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Paula Trujillo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Multiple System Atrophy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, Alterity Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Reliable biomarkers are essential for tracking disease progression and advancing treatments for multiple system atrophy (MSA). In this study, we propose the MSA Atrophy Index (MSA‐AI), a novel composite volumetric measure to distinguish MSA from related disorders and monitor disease progression.

Methods

Seventeen participants with an initial diagnosis of probable MSA were enrolled in the longitudinal bioMUSE study and underwent 3T MRI, biofluid analysis, and clinical assessments at baseline, 6, and 12 months. Final diagnoses were determined after 12 months using clinical progression, imaging, and fluid biomarkers. Ten participants retained an MSA diagnosis, while five were reclassified as either Parkinson disease (PD, n = 4) or dementia with Lewy bodies (DLB, n = 1). Cross‐sectional comparisons included additional MSA cases ( n = 26), healthy controls ( n = 23), pure autonomic failure ( n = 23), PD ( n = 56), and DLB ( n = 8). Lentiform nucleus, cerebellum, and brainstem volumes were extracted using deep learning‐based segmentation. Z‐scores were computed using a normative dataset ( n = 469) and integrated into the MSA‐AI. Group differences were tested with linear regression; longitudinal changes and clinical correlations were assessed using mixed‐effects models and Spearman correlations.

Results

MSA patients exhibited significantly lower MSA‐AI scores compared to all other diagnostic groups ( p < 0.001). The MSA‐AI effectively distinguished MSA from related synucleinopathies, correlated with baseline clinical severity ( ρ = −0.57, p < 0.001), and predicted disease progression ( ρ = −0.55, p = 0.03). Longitudinal reductions in MSA‐AI were associated with worsening clinical scores over 12 months ( ρ = −0.61, p = 0.01).

Interpretation

The MSA‐AI is a promising imaging biomarker for diagnosis and monitoring disease progression in MSA. These findings require validation in larger, independent cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple System AtrophyHumansFemaleMaleDisease ProgressionAgedMiddle AgedMagnetic Resonance ImagingBiomarkersLongitudinal StudiesParkinson DiseaseCross-Sectional StudiesSeverity of Illness IndexLewy Body DiseaseAtrophy

Stichwörter der Autor:innen

MRIMSAatrophybiomarkerimagingprogression

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Neurology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Alterity Therapeutics, Newark, California, USA.

ORCID-Profile: Paula Trujillo, Kilian Hett, Daniel O Claassen

Förderung

  • NINDS NIH HHS
  • NIA NIH HHS
  • Alterity Therapeutics
  • National Institute on Aging
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Trujillo, P., Hett, K., Cooper, A., Brown, A. E., Iregui, J., Donahue, M. J., Landman, M. E., Biaggioni, I., Bradbury, M., Wong, C., Stamler, D., & Claassen, D. O. (2025). The MSA Atrophy Index ( MSA ‐ AI ): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70106

Vancouver

Trujillo P, Hett K, Cooper A, Brown AE, Iregui J, Donahue MJ, et al. The MSA Atrophy Index ( MSA ‐ AI ): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70106

BibTeX
@article{Trujillo2025,
  author = {Trujillo, Paula and Hett, Kilian and Cooper, Amy and Brown, Amy E and Iregui, Jessica and Donahue, Manus J and Landman, M Erik and Biaggioni, Italo and Bradbury, Margaret and Wong, Cynthia and Stamler, David and Claassen, Daniel O},
  title = {The MSA Atrophy Index ( MSA ‐ AI ): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70106}
}
Kostenlos starten →